Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Methylprednisolone hemisuccinate
Drug ID BADD_D01435
Description A water-soluble ester of methylprednisolone used for cardiac, allergic, and hypoxic emergencies.
Indications and Usage Not Available
Marketing Status approved
ATC Code Not Available
DrugBank ID DB14644
KEGG ID D05000
MeSH ID D008776
PubChem ID 16923
TTD Drug ID Not Available
NDC Product Code 22552-0024; 57582-012; 82298-109; 24002-0015; 52128-152
UNII 5GMR90S4KN
Synonyms Methylprednisolone Hemisuccinate | Hemisuccinate, Methylprednisolone | Methylprednisolone Succinate | Succinate, Methylprednisolone | Urbason-Soluble | UrbasonSoluble | Solu-Medrol | Solumedrol | A-MethaPred | Methylprednisolone Sodium Succinate | Sodium Succinate, Methylprednisolone | Methylprednisolone Hemisuccinate Monosodium Salt | 6 alpha-Methylprednisolone Sodium Hemisuccinate | Methylprednisolone Sodium Hemisuccinate | Sodium Hemisuccinate, Methylprednisolone
Chemical Information
Molecular Formula C26H34O8
CAS Registry Number 2921-57-5
SMILES CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Rash23.03.13.001--Not Available
Schizophrenia19.03.04.001--Not Available
Seizure17.12.03.001--
Shock24.06.02.002--Not Available
Skin atrophy23.01.05.001--
Skin hyperpigmentation23.05.01.003--
Skin striae23.01.05.002--Not Available
Spinal compression fracture15.08.05.004; 14.04.04.003; 12.04.04.001--Not Available
Steroid withdrawal syndrome19.04.02.014; 08.06.02.013; 05.01.02.007--Not Available
Suicidal ideation19.12.01.003--
Tendon rupture12.01.07.003; 15.07.01.008--Not Available
Ulcer08.03.06.001--Not Available
Vertigo17.02.12.002; 04.04.01.003--
Vomiting07.01.07.003--
Weight increased13.15.01.006--
Urine calcium increased13.11.01.039--Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Affect lability19.04.01.001--Not Available
Muscle mass15.05.03.018--Not Available
Cognitive disorder19.21.02.001; 17.03.03.003--
Dyslipidaemia14.08.04.015--Not Available
Lipomatosis14.08.04.011--Not Available
Mental disorder19.07.01.002--Not Available
Abnormal behaviour19.01.01.001--Not Available
Psychotic disorder19.03.01.002--
Chorioretinopathy06.09.01.006--Not Available
Epidural lipomatosis17.10.01.012; 14.08.04.019--Not Available
Bladder dysfunction20.03.03.002--Not Available
Functional gastrointestinal disorder07.11.01.016--Not Available
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages